Directorate Change

Regulatory News Service

05 April 2018 07:00 BST


AstraZeneca PLC (the Company) announced today that Rudy Markham and Shriti Vadera will be proposed to shareholders for re-election as Directors for the final time at the Company’s AGM on 18 May 2018.

Mr Markham intends to retire from the Board at the conclusion of the 2019 AGM. Although he has served as a Director for over nine years, the Board continues to consider him to be independent in character and judgement, as evidenced by the way in which he discharges his duties as a Board and Board Committee member. The Board also believes it would be in the best interests of shareholders for him to serve for one further year, during a period of Board changes, given his depth of knowledge of the Company and significant non-executive experience. Subject to his re-election by shareholders, his continued tenure will provide a degree of continuity following the appointment of several new Non-Executive Directors to succeed retiring Board members in 2017 and 2018, and will also facilitate an orderly transition of the roles of Chairman of the Audit Committee and senior independent Director.

Baroness Vadera has informed the Board that she will retire as a Director by 31 December 2018, by when she will have served as a Board member for eight years.

The Company will announce related Board Committee changes and Mr Markham’s successor as senior independent Director as soon as possible following these being decided.

The Company’s Annual Report and Form 20-F Information 2017 was published on 6 March 2018.

The Notice of Annual General Meeting 2018 and Shareholders’ Circular will be published in mid-April 2018.

The meeting place for the Annual General Meeting will be the Royal Lancaster London Hotel, Lancaster Terrace, London W2 2TY and the meeting will commence at 2.30 pm (BST) on 18 May 2018.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit and follow us on Twitter @AstraZeneca.


Media Relations





Esra Erkal-Paler


+44 203 749 5638

Karen Birmingham


+44 203 749 5634

Rob Skelding


+44 203 749 5821

Matt Kent


+44 203 749 5906

Gonzalo Viña


+44 203 749 5916

Jacob Lund


+46 8 553 260 20

Michele Meixell


+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Henry Wheeler


+44 203 749 5797

Mitchell Chan

Oncology; Other

+1 240 477 3771

Christer Gruvris

Brilinta; Diabetes

+44 203 749 5711

Nick Stone

Respiratory; Renal

+44 203 749 5716

US Toll-Free


+1 866 381 7277

Adrian Kemp
Company Secretary
AstraZeneca PLC


  • Regulatory